general
Eli Lilly to pay $2.75 billion for Insilico AI-developed drugs
Eli Lilly agreed a $2.75 billion deal with Hong Kong-listed Insilico Medicine to bring AI-developed drugs to the global market, including a $115 million upfront payment and milestone and royalty payments.
Mar 29th 2026 · United States
Insights
- Deal is worth $2.75 billion to commercialize AI-discovered drugs globally.
- Insilico will receive $115 million upfront, with the remainder tied to regulatory and commercial milestones plus royalties.
- The companies have partnered since 2023.
- Insilico is listed in Hong Kong and CEO Alex Zhavoronkov said Eli Lilly has a competitive edge in certain AI areas.
Sources
- China biotech deals hit record as innovative drugs draw interest of multinationals www.scmp.com
- From lab to global markets: HKSTP leads Hong Kong’s rise as a biotech powerhouse www.scmp.com
- Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market www.cnbc.com
- Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market www.cnbc.com
- Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market www.reddit.com